Trial watch: Immune checkpoint blockers for cancer therapy

OncoImmunology

卷:6

Silvia C. Formenti¹  Lorenzo Galluzzi¹  Sandra Demaria¹  Claire Vanpouille-Box¹  Takahiro Yamazaki¹  Claire Lhuillier¹  Laurence Zitvogel²  Fernando Aranda³  Radek Spisek⁴  Jitka Fucikova⁴  Lucillia Bezu⁵  Oliver Kepp⁵  Guido Kroemer⁵ 

[1] Department of Radiation Oncology, Weill Cornell Medical College;

[2] Gustave Roussy Comprehensive Cancer Institute;

[3] Immunoreceptors of the Innate and Adaptive System Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS);

[4] Sotio a.c.;

[5] Université Paris Descartes/Paris V;

关键词: atezolizumab;    avelumab;    durvalumab;    ipilimumab;    nivolumab;    pembrolizumab;   

DOI  :  10.1080/2162402X.2017.1373237

来源: DOAJ

【 摘 要 】

Immune checkpoint blockers (ICBs) are literally revolutionizing the clinical management of an ever more diversified panel of oncological indications. Although considerable attention persists around the inhibition of cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1, best known as PD-1) signaling, several other co-inhibitory T-cell receptors are being evaluated as potential targets for the development of novel ICBs. Moreover, substantial efforts are being devoted to the identification of biomarkers that reliably predict the likelihood of each patient to obtain clinical benefits from ICBs in the absence of severe toxicity. Tailoring the delivery of specific ICBs or combinations thereof to selected patient populations in the context of precision medicine programs constitutes indeed a major objective of the future of ICB-based immunotherapy. Here, we discuss recent preclinical and clinical advances on the development of ICBs for oncological indications.

【 授权许可】

Unknown